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Abstract
Two unusual cases of hemophagocytic lymphohistiocytosis (HLH) complicating aplastic anemia (AA) are described. Each 
patient had a history of preexisting acute hepatitis of unknown cause at the time of HLH diagnosis and infection-associated 
secondary HLH. They developed high fever and pancytopenia. Hemophagocytes were seen in the bone marrow. With steroid 
(in combination with etoposide and CyA in 1 patient), high fever disappeared and the patients’ liver function gradually 
recovered. As severe pancytopenia persisted, bone marrow became acellular and AA was diagnosed. Since HLH is known 
to be able to cause an aplastic bone marrow if untreated for a prolonged time, it is therefore in line that hepatitis-associated 
AA may also be associated with HLH. 
Aplastic anemia-associated HLH has been reported rarely, and problems in the diagnostic procedure are discussed.
(Turk J Hematol 2010; 27: 38-42)
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Özet
Bu makalede hemofagositik sendrom (HLH) tanÕsÕ alÕp daha sonra aplastik anemi (AA) geliýen 2 hasta sunulmuýtur. Her 2 
hastada da HLH tanÕsÕndan önce etyolojisi net olarak konulmamÕý akut hepatit öyküsü vardÕ ve bu enfeksiyon nedeni ile 
HLH’leri enfeksiyon iliýkili HLH olarak deúerlendirilmiýti. ûki olguda da ateý ve pansitopeni vardÕ. Hemofagositoz iki olguda 
da kemik iliúi aspirasyon materyalinde gösterilmiýti. Bir olguda steroid diúerinde steroide ek olarak etoposid ve siklosporin   
(CyA) ile yüksek ateý ve karaciúer fonksiyonlarÕnda düzelme saptanmaya baýlanmÕýtÕ. Tedaviye raúmen aúÕr sitopeninin 
devam etmesi üzerine kemik iliúinin tekrar deúerlendirilmesi sonucunda hastalara aplastik anemi tanÕsÕ konuldu. 
Hemofagositik sendrom uzun süreli tedavi edilmediúinde kemik iliúinde aplaziye neden olabilir, bu nedenle hepatite baúlÕ 
geliýen aplastik anemilerin geliýim sürecinde HLH’ da olabilir. (Turk J Hematol 2010; 27: 38-42)
Anahtar kelimeler: Hemofagositoz, aplastik anemi, hepatit
Geliý tarihi: 14 Aúustos 2008    Kabul tarihi: 8 Nisan 2009Introduction 
Differential diagnosis of hemophagocytic lymphohistiocyto-
sis (HLH) and aplastic anemia (AA) is very confusing for a clini-
cian who must initiate life-saving therapy with immunosuppres-
sive/immunomodulatory agents in time [1-3]. Brown et al. [4] 
reported that post-hepatitis AA typically occurs in young, previ-
ously healthy males with self-limited but severe liver inflamma-
tion with very high serum aminotransferase and bilirubin levels; 
profound pancytopenia follows several weeks later.
We present herein our experience with two adolescent 
boys ages 11 and 12 years who both presented with hyper-
bilirubinemia and secondary HLH resulting in AA. Both dis-
eases may have some similar immune-mediated conditions 
involving the activation of T lymphocytes. Moreover, immuno-
suppressive therapy with antithymocyte globulin (ATG) and 
cyclosporine (CyA) is very effective for AA, while intensive 
immunosuppressive therapy with ATG and CyA might be a 
useful strategy for steroid-resistant HLH [5].
Aplastic anemia is an immune-mediated disease that is 
associated with increased apoptosis of bone marrow stem 
cells. The increase in apoptosis is due to various cytokines that 
inhibit hematopoiesis, produced by activated T-cells. As is well 
known, HLH is characterized by a systemic activation of mac-
rophages/histiocytes, which are induced to undergo phagocy-
tosis of hematopoietic elements. This hyperinflammatory con-
dition is associated with genetic inheritance, infection, malig-
nancy, and immune deficiencies. The cardinal symptoms are 
prolonged fever, cytopenias, hepatosplenomegaly, and hemo-
phagocytosis by activated, morphologically benign macro-
phages. Biochemical markers include elevated ferritin and tri-
glycerides and low fibrinogen. Impaired function of natural killer 
(NK) and cytotoxic T-cells is characteristic. Two forms of HLH, 
primary (genetic) and secondary (acquired), have been report-
ed. Secondary HLH has been reported in association with a 
variety of conditions [6].  Children with HLH have a higher prob-
ability of malignancy, suggesting a possible predisposing role. 
However, there are only rare reports of an association between 
AA and HLH.  
Generally, the diagnosis of HLH is difficult unless there is 
suspicion. HLH initially may masquerade as a normal infection 
since all symptoms may be common. 
Case Reports 
Written informed consent was obtained from all patients.
Case 1: A 12-year-old boy was followed with hepatitis in a 
local health center for 40 days. Serologic tests for Epstein-Barr 
virus (EBV), cytomegalovirus (CMV), herpes simplex virus 
(HSV)-I, HSV-II, hepatitis B virus (HBV), hepatitis C virus (HCV), 
hepatitis A virus (HAV), and parvovirus B-19 were either nega-
tive or consistent with prior exposure. As liver enzymes 
remained elevated (AST 1975 U/L, ALT 2950 U/L) and total 
bilirubin increased to 4.73 mg/dl, with international normalized 
ratio (INR) of 4.67, he was referred to our hospital. Persistent 
pancytopenia was noticed, and he was consulted to the hema-
tology ward after 25 days. The patient met the diagnostic cri-
teria of HLH described by the Histiocyte Society [2]. Bone 
marrow aspiration was performed and showed an increased 
number of histiocytes with hemophagocytosis. As he was sus-
pected to have infection-associated secondary HLH, steroid 
therapy was started (dexamethasone 10 mg/m2 in the begin-
ning and tapered after 2 weeks, planned for a total period of 8 
weeks). After steroid, the long-lasting fever disappeared in 2 
days and there was an unexpected rapid resolution of hepato-
splenomegaly (each 2 cm below the costal margin). Although 
the clinical manifestations, which were attributed to hypercyto-
kinemia, were controlled with steroid, the pancytopenia per-
sisted even after etoposide was added to the HLH regimen 
after a 4-week period. Bone marrow biopsy performed after 6 
weeks of HLH treatment due to no response of cytopenia 
revealed AA. He was lost 25 days after ATG treatment due to 
aspergillus in the lung and pseudomonas bacteremia. 
Case 2: An 11-year-old boy was followed with persistent 
hepatitis in a local health center for 2 months until gastrointes-
tinal bleeding was detected. Viral documentation was normal. 
Liver enzymes remained elevated (AST 2930 U/L, ALT 3460 
U/L), INR increased to 6.3, and he was referred to our hospital. 
Pancytopenia and fever were noticed and he was consulted to 
the hematology ward after 15 days. The liver biopsy performed 
before hematology consultation revealed infection. The patient 
was diagnosed as secondary HLH after an increased number 
of histiocytes with hemophagocytosis were noticed in the bone 
marrow aspiration, supported by decreased fibrinogen and 
increased ferritin, which until the HLH diagnosis were thought 
to be due to numerous transfusions. He was given dexameth-
asone at a dose of 10 mg/m2. Fever and splenomegaly disap-
peared in the first week, but pancytopenia resulting in near-
fatal infection persisted. Granulocyte colony-stimulating factor 
(G-CSF) was added to steroid treatment due to no hemato-
logical relief, and bone marrow biopsy was done. His parents 
refused any treatment for AA and the patient died due to 
uncontrolled bleeding and sepsis.
Discussion 
Both of the presented patients had no family history sug-
gestive of familial HLH. The patients died before any muta-
tional analysis or NK cell function studies could be performed. 
The diagnosis of secondary HLH, therefore, is based on fulfill-
ment of a minimum of five clinical criteria [6]. Gupta et al. [7] 
mentioned in their commentary that despite the availability of 
genetic and immunological tests in the diagnosis of HLH, there 
is a lack of a confirmatory diagnostic test for acute situations. 
There are also no clear-cut definitions for HLH bone marrow 
infiltration. Three smears with at least 2 histiocytes demonstrat-
ing hemophagocytosis on each are suggested for HLH diagno-
sis, which were detected in both of our patients [7]. No fatty 
infiltration was detected during HLH diagnosis. Bone marrow 
examination showed normal maturation of the three series  
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Table 1. Findings of patients ( ND: not done)
    Case 1  Case 2
Clinical findings  
Fever   +  +
Hepatomegaly  2 cm  1.5 cm
Splenomegaly  2 cm  2 cm
Infection +  +
Jaundice +  +
Bleeding -  +
Laboratory findings    
Hemoglobin gr/dl  
  At the beginning of complainment  9.6  10.8
  At the admission our hospital  5.6  6.8
  At the diagnosis of HLH  3.6  8.7( With transfusions)
  At the diagnosis of AA  3.7  7.5
WBC mm3  
  At the beginning of complainment  12.600  17.000
  At the admission our hospital  5400  6700
  At the diagnosis of HLH  3000  1400
  At the diagnosis of AA  2200  1100
Platelet mm3  
  At the beginning of complainment  178.000  186.000
  At the admission our hospital  98.000  79.000
  At the diagnosis of HLH  6000  8000
  At the diagnosis of AA  9000  4000
Reticulocyte  <0.1  0
AST Õu/L  
  At the beginning of complainment  1108  2089
  At the admission our hospital  1975  1790
  At the diagnosis of HLH  46  47
  At the diagnosis of AA  44  39
ALT Õu/L  
  At the beginning of complainment  1963  2298
  At the admission our hospital  2950  1810
  At the diagnosis of HLH  27  45
  At the diagnosis of AA  660  43
bilirubin  
  At the beginning of complainment  4.8  Not known
  At the admission our hospital  1.35  1.77
Triglyceride mg/dL  
  At the diagnosis of HLH  456  780
  At the diagnosis of AA  115  ND
Fibrinogen g/dL  
  At the admission our hospital  ND  180
  At the diagnosis of HLH  80  56
  At the diagnosis of AA  170  ND
Bone marrow aspiration   
  At the diagnosis of HLH  hemophagocytic features  hemophagocytic features
  At the diagnosis of AA  Bone marrow failure, hypoplasia  Hypoplasia 
Bone marow biopsy  
  At the diagnosis of AA  devoid of hematopoietic elements,   Diminished hematopoietic elements, increased 
    fat and reticulum cells  showing largely fatty tissue and reticulum cellswithout dysplastic features or any blast. The most prominent 
feature was an increase in hemophagocytosing histiocytes. 
Based on these findings, the patients were diagnosed as HLH 
and not AA. Then, after 15-21 days of HLH treatment, the 
bone marrow became severely hypoplastic. However, the 
hemophagocytic features that were apparent before the HLH 
regimen had disappeared in both patients.
Both patients were diagnosed as having severe bone mar-
row failure after HLH that was similar to severe AA. Severe 
pancytopenia with fatty infiltration of the bone marrow is char-
acteristic of AA, but high fever or liver dysfunction is not com-
mon if there is no coexisting infection. 
Hemophagocytic lymphohistiocytosis and AA represent 
distinct disease entities, but they have some pathologically 
similar aspects with activation of T lymphocytes. As mentioned 
in the literature, HLH can be diagnosed before or after AA 
[8-10]. In our patients, post-hepatitis AA, or HLH associated 
with an undiagnosed viral infection in a patient with AA, or a 
coexistence of HLH and AA could be considered in the differ-
ential diagnosis.  However, no fatty change of the marrow was 
found in the beginning, and its cellularity was not severely 
depressed at the time of admission, while hemophagocytic 
histiocytes were prominent.
These findings were characteristic of HLH rather than 
AA. The diagnosis of AA is often difficult because of the 
presence of local hemapoietically active spots that can lead 
to an erroneous assessment before fatty bone marrow. 
Thus, marrow examinations need to be repeated if pancyto-
penia persists. The histiocyte count is sometimes increased 
in AA just like plasma cells, but this is a relative increase and 
is not associated with hemophagocytosis. Ost et al. [11] 
reported that the cellularity of the marrow was decreased in 
some patients and this tissue was severely hypoplastic, 
even in some children who had not been treated with cyto-
static drugs. They also reported that the histological pattern 
in HLH resembles that of chronic persistent hepatitis. In 
other words, there is a potential link between AA, HLH and 
hepatitis-associated AA [11]. 
Hyperbilirubinemia usually coexists with pancytopenia in HLH, 
while bone marrow failure secondary to acute hepatitis generally 
occurs after the hepatitis has resolved if the diagnosis is AA. 
Immunosuppressive therapy with ATG and CyA, which is a com-
mon treatment strategy for severe AA, is sometimes used suc-
cessfully for HLH, especially for steroid-refractory HLH [5,12].
Impaired function of NK cells and cytotoxic T-cells is char-
acteristic for both genetic and acquired forms of HLH. 
Frequent triggers are infectious agents, mostly viruses of the 
herpes group [13,14]. HLH has been identified to be related 
with genes encoding perforin (PRF1/FHL2), Munc 13-4 
(UNC13D/FHL3), and syntaxin-11 (STX11/FHL4). In order to 
show the relation of AA and HLH, Solomou et al. [15] studied 
perforin levels in patients with AA. They found that in AA dis-
ease with hematopoietic stem cells, which were destructed 
by activated T-cells and Th1 cytokines, perforin protein levels 
were very low or absent, and perforin granules were com-
pletely diminished [15]. NK cells are the predominant perforin-
containing cell type. As a result, NK cell cytotoxicity in these 
patients was significantly decreased [13]. In one of the HLH 
subgroups with normal perforin levels, syntaxin-deficient 
patients, it was shown very recently that their NK cells failed 
to degranulate when they encountered susceptible target 
cells [16,17].
Patients with HLH, however, cannot control the hyperin-
flammatory response which, if untreated, is fatal. Awareness of 
the clinical symptoms and of the diagnostic criteria of HLH is 
important to start life-saving therapy with immunosuppressive/
immunomodulatory agents in time. Therefore, we suggest that 
patients with hepatitis who develop pancytopenia and high 
liver enzymes that remain elevated for longer than expected 
should be examined with bone marrow aspiration and biopsy 
for demonstration of hemophagocytosis or for bone marrow 
failure resulting in AA. 
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